Table 4.
Comparison of the pre- and 24-week post-therapy variables in CHC patients stratified by therapeutic response.
| SVR (+) (n = 372) | Paired t-Test p Values | SVR (−) (n = 78) | Paired t-Test p Values | |||
|---|---|---|---|---|---|---|
| Factors | Pre-TherapyValue | Post-TherapyValue | Pre-TherapyValue | Post-TherapyValue | ||
| BMI | 24.84 ± 3.63 | 24.35 ± 3.51 | <0.001 * | 25.72 ± 4.09 | 24.87 ± 3.62 | <0.001 * |
| ALT (U/L) | 97.18 ± 88.37 | 20.0 ± 10.5 | <0.001 * | 79.80 ± 63.85 | 63.7 ± 43.3 | 0.151 |
| TC (mg/dL) | 171.53 ± 32.75 | 184.28 ± 37.39 | <0.001 * | 172.91 ± 29.62 | 174.29 ± 36.12 | 0.7021 |
| TGs (mg/dL) | 101.21 ± 46.21 | 120.54 ± 74.75 | <0.001 * | 113.57 ± 66.05 | 102.77 ± 42.88 | 0.059 |
| Platelet count (103 cells/mm) | 181.27 ± 57.86 | 184.10 ± 55.68 | 0.243 | 156.89 ± 58.72 | 149.40 ± 54.55 | 0.179 |
| HOMA-IR | 2.89 ± 4.70 | 2.83 ± 3.96 | 0.5493 | 4.42 ± 5.73 | 5.40 ± 11.55 | 0.7332 |
| APRI | 1.47 ± 1.63 | 0.418 ± 0.297 | <0.001 * | 1.74 ± 1.83 | 1.28 ± 0.929 | 0.162 |
| Hepatic steatosis (Yes), n (%) | 186 (50) | 193 (51.8) | 0.499 | 34 (43.5) | 37 (47.4) | 0.443 |
| Cirrhosis (Yes), n (%) | 83 (22.3) | 86 (23) | 0.504 | 34 (43.5) | 39 (50) | 0.058 |
| Leptin (ng/mL) | 9.33 ± 9.05 | 9.61 ± 8.77 | 0.15 | 12.2 ± 14.1 | 10.1 ± 12.5 | 0.187 |
| Adiponectin (μg/mL) | 10.1 ± 7.48 | 8.14 ± 5.09 | 0.003* | 8.04 ± 5.16 | 8.77 ± 6.32 | 0.473 |
| Leptin (ng/mL)/adiponectin (μg/mL) ratio | 1.96 ± 4.07 | 2.26 ± 3.57 | 0.188 | 2.44 ± 2.96 | 3.02 ± 6.43 | 0.506 |
| PAI-1 (ng/mL) | 6.76 ± 2.98 | 9.08 ± 4.43 | 0.003* | 6.56 ± 3.69 | 6.45 ± 4.42 | 0.9355 |
SVR: sustained virological response; *: p < 0.05; BMI: body mass index; ALT: alanine aminotransferase; TC: total cholesterol; TGs: triglycerides; HOMA-IR: homeostasis model assessment-estimated insulin resistance; APRI: aspartate aminotransferase to platelet ratio index; PAI-1: plasminogen activator inhibitor-1.